Tumor-associated urokinase-type plasminogen activator: significance in breast cancer

Urokinase-type plasminogen activator (u-PA), a proteolitic enzyme, capable of degrading type 4 collagen, is supposed to be involved in degradation of extracellular matrix during cancer invasion. Evidence has been presented that primary breast cancer patients with tumors containing high levels of u-P...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of gynaecological oncology Vol. 17; no. 4; p. 315
Main Authors Torre, E A, Fulco, R A
Format Journal Article
LanguageEnglish
Published Italy 1996
Subjects
Breast Neoplasms - enzymology
Humans
Prognosis
Urokinase-Type Plasminogen Activator - metabolism
Online AccessGet more information

Cover

More Information
Summary:Urokinase-type plasminogen activator (u-PA), a proteolitic enzyme, capable of degrading type 4 collagen, is supposed to be involved in degradation of extracellular matrix during cancer invasion. Evidence has been presented that primary breast cancer patients with tumors containing high levels of u-PA experience a worse prognosis. u-PA and its inhibitor, type 1 plasminogen activator inhibitor (PAI-1), are potentially important prognostic factors in breast cancer to identify patients at high risk for recurrence and also in the classification of clinically important subgroups.
ISSN:0392-2936